The Relationships between Serum sTWEAK, FGF-23 Levels, and Carotid Atherosclerosis in Renal Transplant Patients

REFERENCES

• Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;15(378):1419–1427.
   Google Scholar
• Toz H, Duman S, Altunel E, . Intima media thickness as a predictor of atherosclerosis in renal transplantation. Transplant Proc. 2004;36:156–158.
   PubMed Web of Science ®Google Scholar
• Sánchez-Escuredo A, Pastor MC, Bayés B, . Inflammation, metalloproteinases, and growth factors in the development of carotid atherosclerosis in renal transplant patients. Transplant Proc. 2010;42:2905–2907.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Qureshi AR, Carrero JJ, . Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. Am J Nephrol. 2010;31:214–221.
   PubMed Web of Science ®Google Scholar
• Cofan F, Arias M, Nuñez I, . Impact of carotid atherosclerosis as assessed by B-mode ultrasonography on the evolution of kidney transplantation. Transplant Proc. 2007;39:2236–2238.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, . Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:916–922.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Ortiz A, . Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6:785–792.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Carrero JJ, Ortiz A, . Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1716–1723.
   PubMed Web of Science ®Google Scholar
• Carrero JJ, Ortiz A, Qureshi AR, . Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:110–118.
   PubMed Web of Science ®Google Scholar
• Gungor O, Kircelli F, Asci G, . Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients? J Nephrol. 2012;13. doi:10.5301/jn.5000121
   Google Scholar
• Jain M, Jakubowski A, Cui L, . A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation. 2009;119:2058–2068.
   PubMed Web of Science ®Google Scholar
• Balci M, Kirkpantur A, Gulbay M, Gurbuz OA. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int. 2010;14:425–432.
   PubMed Web of Science ®Google Scholar
• Ashikaga E, Honda H, Suzuki H, . Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial. 2010;14:315–322.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Cassiano L, Lofton T, . A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15:837–846.
   PubMed Web of Science ®Google Scholar
• Economidou D, Dovas S, Papagianni A, Pateinakis P, Memmos D. FGF-23 levels before and after renal transplantation. J Transplant. 2009;2009:379082.
   PubMedGoogle Scholar
• Agrotis A, Kanellakis P, Kostolias G, . Proliferation of neointimal smooth muscle cells after arterial injury. Dependence on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9. J Biol Chem. 2004;279:42221–42229.
   PubMed Web of Science ®Google Scholar
• Lewis CD, Olson NE, Raines EW, Reidy MA, Jackson CL. Modulation of smooth muscle proliferation in rat carotid artery by platelet-derived mediators and fibroblast growth factor-2. Platelets. 2001;12:352–358.
   PubMed Web of Science ®Google Scholar
• Sigala F, Savvari P, Liontos M, . Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NF-κB pathway. J Cell Mol Med. 2010;14:2273–2280.
   PubMed Web of Science ®Google Scholar
• Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol. 2010;23:619–625.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TWEAKR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:241–249.
   PubMed Web of Science ®Google Scholar
• Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine. 2007;40:1–16.
   PubMed Web of Science ®Google Scholar
• Muñoz-García B, Moreno JA, López-Franco O, . Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2009;29:2061–2068.
   PubMed Web of Science ®Google Scholar
• Sanz AB, Sánchez-Nino MD, Izquierdo MC, . TWEAK, the facilitator of acute kidney injury. Nefrologia. 2008;28:587–592.
   PubMedGoogle Scholar
• Jakubowski A, Browning B, Lukashev M, . Dual role for TWEAK in angiogenic regulation. J Cell Sci. 2002;115: 267–274.
   PubMed Web of Science ®Google Scholar